FGFR3 fusion	Urothelial Cancer	FGFR3 fusion	Urothelial Cancer	erdafitinib Sensitive: B - Late Trials erdafitinib Sensitive : B	erdafitinib Sensitive: B - Late Trials erdafitinib Sensitive : B
FGFR3 fusion	Urothelial Cancer	FGFR3 fusion	Urothelial Cancer	pemigatinib Sensitive: C2 – Inclusion Criteria pemigatinib Sensitive : C2	pemigatinib Sensitive: C2 – Inclusion Criteria pemigatinib Sensitive : C2
FGFR3 fusion	Solid Tumor	FGFR3 fusion	Solid Tumor	Debio 1347 Sensitive: C3 – Early Trials Debio 1347 Sensitive : C3	Debio 1347 Sensitive: C3 – Early Trials Debio 1347 Sensitive : C3
FGFR3 fusion	Cholangiocarcinoma	FGFR3 fusion	Cholangiocarcinoma	Debio 1347 Sensitive: C3 – Early Trials Debio 1347 Sensitive : C3	Debio 1347 Sensitive: C3 – Early Trials Debio 1347 Sensitive : C3
FGFR3 fusion	Urothelial Cancer	FGFR3 fusion	Urothelial Cancer	B-701 Sensitive: C3 – Early Trials B-701 Sensitive : C3	B-701 Sensitive: C3 – Early Trials B-701 Sensitive : C3
FGFR3 fusion	Solid Tumor	FGFR3 fusion	Solid Tumor	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3

FGFR3 fusion

Associations